{"entity":{"id":"starton-holdings","kind":"company","name":"Starton Holdings","aka":["Starton Holdings, Inc.","Starton Therapeutics","Starton Therapeutics, Inc","Starton Therapeutics Inc."],"tldr":"Starton is a New Jersey company that gives existing cancer medicines continuously, through a small pump under the skin or a slow-release tablet, instead of as a daily dose. Its lead product, STAR-LLD, is a continuous low-dose form of lenalidomide being tested in multiple myeloma that has come back or stopped responding.","summary":"Starton Holdings, Inc., with principal executive offices and a laboratory in Paramus, New Jersey, filed a registration statement for its initial public offering with the SEC in 2026, with the Nasdaq symbol STA applied for. The filing describes a clinical-stage company whose platform delivers approved, off-patent medicines continuously, by ambulatory subcutaneous pump, oral controlled-release tablet or transdermal patch, to lower peak blood levels and improve tolerability, and says it is focused first on blood cancers.\n\nIts lead programme STAR-LLD is continuous low-dose lenalidomide, the active ingredient of Revlimid, developed as a subcutaneous formulation (STAR-LLD-SC) and an oral controlled-release formulation (STAR-LLD-OCR) in parallel. The filing states that Phase 1 and 1b studies of STAR-LLD-SC in multiple myeloma are complete and that a Phase 2a study in relapsed or refractory multiple myeloma is under way; it also describes planned investigator-initiated trials with CAR-T cell therapies and T-cell engagers, the first with elranatamab supplied by Pfizer. A transdermal olanzapine patch for chemotherapy-induced nausea and vomiting is on hold. The company's operating subsidiary, Starton Therapeutics, is the sponsor of the registered trial NCT06087653.","asOf":"2026-11-04","links":[{"label":"SEC EDGAR: Starton Holdings S-1/A, October 2026","url":"https://www.sec.gov/Archives/edgar/data/2049977/000121390026113388/ea0225405-18.htm"},{"label":"Official website","url":"https://www.startontx.com/"},{"label":"ClinicalTrials.gov: continuous subcutaneous lenalidomide in multiple myeloma (NCT06087653)","url":"https://clinicaltrials.gov/study/NCT06087653"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["star-lld"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06087653"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read from the S-1/A filed on EDGAR on 28 October 2026 (business summary, cover page and corporate information) on 4 November 2026. The offering had not priced when read, so no IPO round is recorded. Founding year not read."],"hq":"Paramus, NJ","country":"US","companyType":"biotech","website":"https://www.startontx.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/starton-holdings/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"star-lld","kind":"drug","name":"STAR-LLD","route":"/drugs/star-lld/"}],"trial":[{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/"}]}}